首页> 中文期刊> 《药学与临床研究》 >良性前列腺增生与勃起功能障碍的机制联系及相关药物研发进展

良性前列腺增生与勃起功能障碍的机制联系及相关药物研发进展

         

摘要

Benign prostatic hyperplasia and erectile dysfunction are the two major diseases that troubled middle-aged and old men,the concurrency rate of the two diseases is increasing as age increases.Epidemi-ological studies have shown a significant correlation between the two diseases,therefore,it is of great signifi-cance to find the relationship between the two diseases starting with pathophysiological mechanism.This arti-cle summarized the research progress of down regulation of the nitric oxide-cyclic guanosine monophosphate pathway,enhancement of Rho-kinase signaling,activation of α1adrenergic receptor and cysteine-H2S signal regulation in recent years,and then it summarized the research and development of 5 phosphodiesterase in-hibitors,soluble guanosine cyclase regulators and Rho-kinase inhibitors,the ultimate purpose of this article is to provide useful information for the elucidation of the pathophysiological basis of the two diseases and new ideas for the search for potential targets related to disease and the development of new drugs.%良性前列腺增生与勃起功能障碍是困扰中老年男性的两大疾病,随着年龄增大,两种疾病的并发率也在不断增大.多项流行病学研究显示,两者存在显著的相关性,因此从病理生理机制入手寻找两者联系具有重要意义.本文综述了近年来在NO-cGMP通路信号的下调、Rho激酶信号通路活性增强、α1肾上腺素受体的激活以及半胱氨酸与H2S信号调节等机制上的研究进展,总结了PDE5抑制剂、sGC调节剂及Rho激酶抑制剂的相关研发进展,为两种疾病的病理生理基础的阐明提供了有益信息,也为疾病潜在靶标的寻找及新药研发提供新的启发.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号